Skip to content

Non-invasive cell-free DNA-based approach for the diagnosis of aneuploidies in spontaneous abortion.

Jul 2026 · Fetal Diagnosis and Therapy · pp. 1-14 · 0 citations
Medicine

Abstract

Objective

Spontaneous abortion is the most common complication in early pregnancy, with chromosomal abnormalities accounting for up to 50% of first-trimester losses. Conventional genetic analyses often rely on invasive procedures that may be limited by technical challenges and patient reluctance. This study aimed to evaluate the feasibility and diagnostic performance of cell-free DNA (cfDNA) based testing as a non-invasive approach for detecting chromosomal abnormalities in first-trimester spontaneous abortion.

Methods

This study included pregnant individuals diagnosed with spontaneous abortion between 7+0 and 14+6 weeks of gestation from 2022 to 2025. cfDNA was extracted from maternal plasma and analyzed using the VeriSeq™ NIPT Solution v2 (Illumina). A subset of participants who underwent dilation and curettage (D&C) also had fetal tissue analyzed via chromosomal microarray (CMA), which served as the reference standard. Primary outcomes included the rate of non-informative results (NIR), fetal fraction (FF) ≥4%, and detection rate of chromosomal abnormalities. Sensitivity, specificity, and predictive values of cfDNA were calculated relative to CMA.

Results

A total of 299 participants underwent cfDNA testing, of whom 28 also had fetal tissue CMA. The mean FF was 5.83%, with 231/299 (77.3%) samples having FF ≥4%. NIR occurred in 6 cases (2.0%), while 62 (20.7%) had FF <4%. Among cfDNA results with FF ≥4%, 130/231 (56.3%) showed chromosomal abnormalities, with trisomy 16 being the most common. In the D&C subgroup, cfDNA and CMA results were fully concordant (sensitivity and specificity 100%). FF was positively correlated with gestational age (r = 0.42, p < 0.001).

Conclusions

cfDNA-based testing represents a feasible non-invasive method for detecting chromosomal abnormalities following first-trimester pregnancy loss. It may offer an effective alternative to invasive genetic testing, particularly when tissue sampling is unavailable.

View source

Similar papers

Review Open access Aug 2026

Diagnostic accuracy of cell-free DNA-based non-invasive prenatal testing for fetal aneuploidies: a systematic review

Background Through a more precise and safer means of diagnosing foetal aneuploidies, non-invasive prenatal testing (NIPT) with cell-free DNA (cfDNA) has revolutionized prenatal screening and removed the necessity of invasive diagnostic procedures. The aim of the systematic review was to determine the limits of, diagnos...

Sharif Alhajlah · 0 citations
Open access Aug 2026

Pilot Evaluation of ddPCR-Based NIPT for Fetal Trisomy Screening in Advanced-Maternal-Age Pregnancies in Mongolia

Background/Objectives: Advanced maternal age (≥35 years) significantly increases the risk of fetal chromosomal abnormalities, particularly trisomies 21, 18, and 13. Non-invasive prenatal testing (NIPT) based on cell-free fetal DNA (cffDNA) in maternal plasma has substantially improved the accuracy and safety of prenata...

Khaliunaa Tuvshinjargal, Gerelsuren Batbayar, Nomuun Oyunbat et al. · 0 citations
Review Aug 2026

Molecular Prenatal Diagnosis of Monogenic Diseases, Towards Non-invasive Procedures.

In this narrative review, we outline the historical progression of, and modern advancements in, prenatal diagnosis for monogenic diseases. Initially dependent on invasive sampling procedures, prenatal diagnosis has evolved through the integration of high-throughput molecular techniques, such as next-generation sequenci...

Camille Verebi, J. Nectoux, Thierry Bienvenu · 0 citations
Open access Sep 2026

Excessively High Maternal Total Cell-Free DNA Concentration and Fetal Growth Restriction in Singleton Pregnancies: A Retrospective Cohort Study

It is suggested that t-cfDNA could potentially serve as an early biomarker for identifying pregnancies at elevated risk of FGR and adverse pregnancy outcomes and is limited by statistical power, warranting cautious interpretation.

Lin Xing, Xiao-Sha Jing, Ting Bai et al. · 0 citations
Open access Sep 2026

Cell-Free DNA Screening After Euploid Embryo Transfer: Concordance With Amniocentesis and Residual Aneuploidy Risk.

OBJECTIVE To assess concordance between cell-free DNA screening and invasive prenatal diagnosis after single euploid embryo transfer following pre-implantation genetic testing for aneuploidy (PGT-A), and estimate residual chromosomal risk. METHOD This retrospective cohort included 1079 singleton ongoing pregnancies a...

Yao Lu, Yaqiong He, Yi Huang et al. · 0 citations
Open access Aug 2026

Non-Invasive Prenatal Testing in Donor-Oocyte Pregnancies: Biological Determinants, Algorithmic Limitations and Clinical Implications.

Donor-oocyte pregnancy should be regarded as a biologically distinct model for cfDNA screening, one that exposes the limits of generic NIPT algorithms and argues for more tailored interpretation.

M. Miscia, Irene Pesaresi, Benedetta Dini et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.